Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,957.50    33.00 (1.71%)
Bid:
1,961.00
Ask:
1,961.50
Spread: 0.50 (0.025%)
Market Cap: £78.45b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

Today 15:30

RNS Number : 3876J
GSK PLC
23 June 2026
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sir Jonathan Symonds

b)

Position/status

Non-Executive Chair

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Purchase of 1,550 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£19.3524

1,550

d)

Aggregated information

 

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2026-06-19

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Elizabeth (Liz) McKee Anderson

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 789 ADS

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.6908

 

789

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Charles Bancroft

b)

Position/status

Senior Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 1,855 ADS

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.6908

1,855

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Anne Beal

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 745 ADS

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.6908

745

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Dietz

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 667 ADS

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.6908

667

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Jeannie Lee

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 802 ADS

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.6908

802

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Vishal Sikka

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 1,266 ADS

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.6908

1,266

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSEMSADEMSEEM
Date   Source Headline
15th Jan 20263:30 pmRNSDirector/PDMR Shareholding
13th Jan 20263:30 pmRNSDirector/PDMR Shareholding
7th Jan 20267:05 amRNSEC approval of Shingrix PFS
7th Jan 20267:00 amRNSPositive phase 3 data for GSK's bepirovirsen
6th Jan 20267:00 amRNSExdensur approved in Japan
5th Jan 20263:30 pmRNSDirector/PDMR Shareholding
5th Jan 20263:00 pmRNSTotal Voting Rights
5th Jan 20267:00 amRNSNucala for adults with COPD approved in China
22nd Dec 20253:30 pmRNSDirector/PDMR Shareholding
22nd Dec 20253:30 pmRNSDirector/PDMR Shareholding
22nd Dec 20257:00 amRNSGSK to lower drug prices and expand access in US
22nd Dec 20257:00 amRNSGSK to lower drug prices and expand access in US
22nd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
18th Dec 20257:00 amRNSTransaction in Own Shares
17th Dec 20257:00 amRNSExdensur (depemokimab ulla) approved by US FDA
17th Dec 20257:00 amRNSTransaction in Own Shares
16th Dec 20257:00 amRNSExdensur (depemokimab) UK MHRA approval
16th Dec 20257:00 amRNSTransaction in Own Shares
15th Dec 20257:00 amRNSTransaction in Own Shares
12th Dec 20251:50 pmRNSNucala receives positive CHMP opinion for COPD
12th Dec 20251:41 pmRNSDepemokimab receives positive CHMP opinion
12th Dec 20257:00 amRNSPositive CHMP opinion on Arexvy for all adults 18+
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:54 pmRNSBlujepa approved in US for gonorrhoea indication
11th Dec 20253:30 pmRNSDirector/PDMR Shareholding
11th Dec 20259:00 amRNSBlock Listing Application
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 20257:00 amRNSGSK'227 US FDA Orphan Drug Designation in SCLC
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20253:30 pmRNSDirector/PDMR Shareholding
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20253:30 pmRNSDirector/PDMR Shareholding
1st Dec 20253:00 pmRNSTotal Voting Rights
1st Dec 20257:00 amRNSTransaction in Own Shares
28th Nov 20257:00 amRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSTransaction in Own Shares
25th Nov 20257:00 amRNSTransaction in Own Shares
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSInitiation of litigation against AnaptysBio Inc
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.